Highlights

  • Mayne Pharma shares rose 4.24% to AUD 2.46 on 22 May 2026, following the release of latest announcement
  • The company announced it had been awarded AUD 13.27 million in legal costs by the Supreme Court of New South Wales.
  • The payment follows Mayne Pharma’s earlier legal success against Cosette Pharmaceuticals.
  • The Court previously dismissed all claims made by Cosette in October 2025.
  • Interest will also be payable in addition to the awarded legal costs amount.

Mayne Pharma Group Ltd (ASX:MYX) shares moved higher during afternoon trade on 22 May 2026, with the stock climbing 4.24% to AUD 2.46 after the company released an update regarding legal proceedings involving Cosette Pharmaceuticals, Inc. Investor attention appeared to focus on the Court’s decision awarding more than AUD 13 million in legal costs to Mayne Pharma following the company’s successful outcome in proceedings related to the termination of a Scheme Implementation Deed.

Although the stock recorded a favourable move during the session, Mayne Pharma shares remain significantly lower on a 12-month basis, down 43.53% over the past year. The latest announcement nevertheless placed the company back in focus as investors assessed the financial implications of the Court ruling and the potential impact of the additional cash recovery.

Mayne Pharma is an Australian specialty pharmaceutical company focused on the development and commercialisation of branded and generic pharmaceutical products. The company has established operations across dermatology and women’s health markets in the United States while also providing contract development and Manufacturing services to customers globally. In addition, the company has a long operating history in oral drug delivery technologies, with several of its pharmaceutical delivery platforms commercialised in products marketed internationally.

Court Orders Cosette to Pay More Than AUD 13 Million

In its ASX release dated 22 May 2026, Mayne Pharma confirmed that the Supreme Court of New South Wales had awarded the company AUD 13,269,328.04 in legal costs following the earlier termination proceedings against Cosette Pharmaceuticals.

The dispute stemmed from events that began in February 2025, when Mayne Pharma and Cosette entered into a Scheme Implementation Deed. However, the situation later escalated after Cosette purported to terminate the agreement, prompting Mayne Pharma to commence legal proceedings in June 2025.

The litigation was heard in the Supreme Court of New South Wales, where Mayne Pharma sought relief in relation to Cosette’s attempted termination of the agreement. The proceedings became a closely watched matter for shareholders given the significance of the proposed transaction and the uncertainty surrounding the dispute.

In October 2025, the Court ruled in favour of Mayne Pharma and dismissed all claims brought by Cosette. At that time, the Court also issued an adverse costs order against Cosette, determining that Cosette would be required to pay Mayne Pharma’s legal costs associated with the proceedings, either as agreed or assessed.

The latest update now provides clarity on the amount payable.

According to the company, the Court has determined that Cosette must pay Mayne Pharma AUD 13,269,328.04 in legal costs, with additional interest also to be paid. The Court is expected to issue further orders shortly to formally implement the judgment, including matters relating to the applicable interest amount, payment timing and Mayne Pharma’s additional costs linked to the costs application process itself.

Market Reacts to Favourable Legal Outcome

The positive share price reaction on 22 May 2026 appeared linked to the financial benefit associated with the Court ruling, particularly as the awarded amount represents a sizeable recovery relative to the company’s current market positioning.

Investors often monitor legal disputes involving listed companies because litigation outcomes can influence both financial performance and broader market sentiment. In Mayne Pharma’s case, the latest judgment not only reinforced the earlier Court decision delivered in October 2025 but also quantified the value of the legal cost recovery.

The inclusion of interest payments on top of the AUD 13.27 million award may also have supported market confidence, although the final amount payable will depend on subsequent Court orders.

While the update does not alter the company’s underlying pharmaceutical operations directly, it potentially improves visibility around cash inflows associated with the proceedings. The market response suggests investors viewed the announcement as a favourable development amid a period in which the company’s share price has remained under pressure over the longer term.

Background to the Legal Proceedings

The dispute between Mayne Pharma and Cosette originated from the proposed transaction announced in early 2025. Following the signing of the Scheme Implementation Deed in February 2025, Cosette later sought to terminate the agreement, leading to legal action from Mayne Pharma.

The proceedings focused on the validity of Cosette’s purported termination and whether the company was entitled to exit the arrangement under the terms of the agreement.

Mayne Pharma initiated proceedings in June 2025, arguing against Cosette’s position. Several months later, in October 2025, the Court dismissed Cosette’s claims and ruled in favour of Mayne Pharma.

At the same time, the Court ordered Cosette to cover Mayne Pharma’s legal costs, although the precise amount had not yet been determined at that stage.

The latest judgment therefore represents the next major step in the proceedings, with the Court now formally assessing the legal costs payable.

Focus Remains on Core Pharmaceutical Operations

Outside the legal proceedings, Mayne Pharma continues to operate across multiple pharmaceutical segments, with particular exposure to women’s health and dermatology products in the United States market.

The company also maintains a contract development and manufacturing Business serving pharmaceutical clients internationally. These operations include formulation development, manufacturing capabilities and drug delivery technologies developed over several decades.

Mayne Pharma states that it has a 40-year history in oral drug delivery innovation, with technologies that have been commercialised through various pharmaceutical products sold globally.

The company’s operations therefore extend beyond a single therapeutic category, incorporating both proprietary products and manufacturing services.

Investors continue to monitor how Mayne Pharma balances operational performance, strategic initiatives and Capital management while navigating industry competition and broader pharmaceutical market conditions.

Investors Assess Financial Implications

The AUD 13.27 million legal cost recovery has become a key point of focus following the latest announcement. Market Participants are likely assessing how the payment, together with interest, could influence Mayne Pharma’s financial position once received.

At the same time, investors may continue to monitor whether any additional developments emerge from the broader dispute or subsequent Court processes relating to payment implementation.

Although today’s announcement provided a favourable legal outcome for the company, MYX shares remain substantially below levels seen a year earlier. This indicates that investors are still weighing broader operational and market considerations alongside the latest Court ruling.

Nevertheless, the update delivered a positive catalyst for the stock during Friday’s session, contributing to renewed market attention on the company.